HGH vs Tesamorelin
FDA Approved vs FDA Approved
monitor Mechanism-based · 55% Both HGH and Tesamorelin affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
HGH Tesamorelin
Weight 22,124 Da 5,135.9 Da
Half-life 3-4 hours (SC), 20-30 minutes (IV) 26-38 minutes
Chain 191 amino acids 44 amino acids
Type Single-chain polypeptide with two disulfide bridges GHRH analog
Key Benefits
HGH
01 Improved body composition (increased lean mass, decreased fat)
02 Enhanced bone mineral density
03 Improved lipid profile
04 Increased exercise capacity
05 Better quality of life and mood
06 Skin, hair, and nail improvements
07 Enhanced recovery and healing
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
HGH
1-4 IU daily (0.33-1.33mg); start low and titrate up / Once daily or split into 2 doses (morning and evening)
Medical GHD (Starting) 0.15-0.3mg/day (0.5-1 IU) Once daily
Medical GHD (Maintenance) 0.4-0.8mg/day (1.2-2.4 IU) Once daily
Anti-Aging/Wellness 1-2 IU/day (0.33-0.67mg) Once daily
Body Recomposition 2-4 IU/day (0.67-1.33mg) Once or twice daily
Performance (Higher Risk) 4-8 IU/day (1.33-2.67mg) Split twice daily
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
HGH
Water retention and fluid accumulation
Joint pain and stiffness
Carpal tunnel syndrome (usually resolves with dose reduction)
Headaches
Numbness/tingling in hands
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Active cancer (may accelerate tumor growth)
Acute critical illness (increased mortality in ICU patients)
Closed epiphyses in children (for growth promotion)
Pregnancy/breastfeeding
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
HGH Tesamorelin
Status FDA Approved FDA Approved
References 4 studies 5 studies
Latest 2024 June 2025
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.